SCHEMBL24176361

SCHEMBL24176361

Cc1ccc(S(=O)(=O)C(C)C)cc1P

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
HTT P42858 2/20 0.34
TP53 P04637 1/20 0.33
ABL1 P00519 1/20 0.33
ALDH1A1 P00352 5/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
RAPGEF4 Q8WZA2 1/20 0.32
GCK P35557 1/20 0.32
PSEN1 P49768 1/20 0.32
PSEN2 P49810 1/20 0.32
APH1B Q8WW43 1/20 0.32
NCSTN Q92542 1/20 0.32
APH1A Q96BI3 1/20 0.32
PSENEN Q9NZ42 1/20 0.32
PKM P14618 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12180488 0.82 LMNA (0.57) LMNATDP1PTGDR2L3MBTL1HTT
SCHEMBL1370542 0.77 LMNA (0.38) LMNATDP1PTGDR2L3MBTL1ABL1
SCHEMBL14978748 0.77 PSEN1 (0.41) LMNATDP1PTGDR2ABL1PSEN1
SCHEMBL1755240 0.77 FLT1 (0.43) LMNATDP1PTGDR2ALDH1A1MAPT
SCHEMBL21331687 0.76 ALDH1A1 (0.42) LMNATDP1ALDH1A1MAPTSMN1; SMN2
SCHEMBL28037659 0.75 ALDH1A1 (0.38) LMNATDP1HTTALDH1A1MAPT
SCHEMBL28037211 0.74 ALDH1A1 (0.41) LMNATDP1ALDH1A1MAPTSMN1; SMN2
SCHEMBL28037182 0.74 ALDH1A1 (0.41) LMNATDP1ALDH1A1MAPTSMN1; SMN2
Ammonia Solution, Strong SCHEMBL28038067 0.74 ALDH1A1 (0.41) LMNATDP1ALDH1A1MAPTSMN1; SMN2
SCHEMBL14120260 0.74 LMNA (0.43) LMNATDP1PTGDR2L3MBTL1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858879-B2 PARG inhibitors and method of use thereof CITY OF HOPE (US) 2024-01-02 US disclosed
US-20220002231-A1 PARG INHIBITORS AND METHOD OF USE THEREOF CITY OF HOPE 2022-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220002231-A1 PARG INHIBITORS AND METHOD OF USE THEREOF PARG, PARP12, PARP15 LMNA 864/4885TDP1 284/4885PTGDR2 3245/4885
US-11858879-B2 PARG inhibitors and method of use thereof PARG, PARP12, PARP15 LMNA 864/4885TDP1 284/4885PTGDR2 3245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.